Dabigatran etexilate mesylate and Blood immunoglobulin g decreased - a phase IV clinical study of FDA data

Summary:

Blood immunoglobulin g decreased is reported only by a few people who take Dabigatran Etexilate Mesylate.

The phase IV clinical study analyzes which people take Dabigatran etexilate mesylate and have Blood immunoglobulin g decreased. It is created by eHealthMe based on reports of 333 people who have side effects while taking Dabigatran etexilate mesylate from the FDA, and is updated regularly.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 10, 2022

333 people reported to have side effects when taking Dabigatran etexilate mesylate.
Among them, 2 people (0.6%) have Blood immunoglobulin g decreased.


What is Dabigatran etexilate mesylate?

Dabigatran etexilate mesylate has active ingredients of dabigatran etexilate mesylate. eHealthMe is studying from 47 Dabigatran etexilate mesylate users for its effectiveness, alternative drugs and more.

What is Blood immunoglobulin g decreased?

Blood immunoglobulin g decreased is found to be associated with 591 drugs and 301 conditions by eHealthMe.

Number of Dabigatran etexilate mesylate and Blood immunoglobulin g decreased reports submitted per year:

Could Dabigatran etexilate mesylate cause Blood immunoglobulin g decreased?

Gender of people who have Blood immunoglobulin g decreased when taking Dabigatran etexilate mesylate *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Blood immunoglobulin g decreased when taking Dabigatran etexilate mesylate *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 100 %
  • 60+: 0.0 %

Common drugs people take besides Dabigatran etexilate mesylate *:

  1. Topiramate: 2 people, 100.00%
  2. Synthroid: 2 people, 100.00%
  3. Acetaminophen: 2 people, 100.00%
  4. Cetirizine Hydrochloride: 2 people, 100.00%
  5. Colchicine: 2 people, 100.00%
  6. Diazepam: 2 people, 100.00%
  7. Diphenhydramine Hydrochloride: 2 people, 100.00%
  8. Ibuprofen: 2 people, 100.00%
  9. Liothyronine Sodium: 2 people, 100.00%
  10. Methylprednisolone: 2 people, 100.00%

Common side effects people have besides Blood immunoglobulin g decreased *:

  1. Weight Increased: 2 people, 100.00%
  2. Fever: 2 people, 100.00%
  3. Injection Site Pain: 2 people, 100.00%
  4. Infusion Site Pruritus (severe itching at infusion site): 2 people, 100.00%
  5. Infusion Related Reaction: 2 people, 100.00%
  6. Hypotension (abnormally low blood pressure): 2 people, 100.00%
  7. Hypoaesthesia (reduced sense of touch or sensation): 2 people, 100.00%
  8. Headache (pain in head): 2 people, 100.00%
  9. Gout (uric acid crystals building up in the body): 2 people, 100.00%
  10. Fluid Retention (an abnormal accumulation of fluid in the blood): 2 people, 100.00%

Common conditions people have *:

  1. Headache (pain in head): 2 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Dabigatran etexilate mesylate and have Blood immunoglobulin g decreased?

Check whether Blood immunoglobulin g decreased is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Blood immunoglobulin g decreased and when was it recovered:

Expand to all the drugs that have ingredients of dabigatran etexilate mesylate:

Alternative drugs to, pros and cons of Dabigatran etexilate mesylate:

Blood immunoglobulin g decreased treatments and more:

COVID vaccines that are related to Blood immunoglobulin g decreased:

Common drugs associated with Blood immunoglobulin g decreased:

All the drugs that are associated with Blood immunoglobulin g decreased:

Common conditions associated with Blood immunoglobulin g decreased:

All the conditions that are associated with Blood immunoglobulin g decreased:

How the study uses the data?

The study uses data from the FDA. It is based on dabigatran etexilate mesylate (the active ingredients of Dabigatran etexilate mesylate) and Dabigatran etexilate mesylate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: